Vaccine (mRNA vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Arcturus Therapeutics
ARCT-021 is a vaccine made of a self-replicating mRNA encoding the full-length SARS-CoV-2 spike protein, formulated in a lipid nanoparticle. After administration, the mRNA is translated into spike protein, which can activate humoral and cellular immune responses. It is studied for active immunization against COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07390968 | Phase 2 | Hematopoietic and Lymphatic System Neoplasm | Not yet recruiting | ARCT |
| NCT05037097 | Phase 1/2 | COVID-19 | Completed | ARCT |
| NCT04668339 | Phase 2 | Covid19 | Terminated | ARCT |
| NCT04480957 | Phase 1/2 | SARS-CoV-2 | Completed | ARCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematopoietic and Lymphatic System NeoplasmCorona Virus InfectionCOVID-19Covid19SARS-CoV InfectionSARS-CoV-2SARS-CoV-2 Infection
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARCT page.
See ARCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARCT catalysts and pipeline →